GRAIL (GRAL) Rockets to Record High on Samsung Mega-Deal and Cancer Test Breakthrough
GRAIL, Inc. shares soared to record highs this week after the company announced a strategic collaboration with Samsung. On October 16, GRAIL revealed a binding agreement in which Samsung C&T and Samsung Electronics will invest $110 million into GRAIL at $70.05 per sharets2.tech. In return, Samsung C&T gains exclusive rights to distribute GRAIL’s Galleri multi-cancer early detection blood test in South Korea, with plans to expand to Japan and Singaporets2.tech. Samsung Electronics will explore technology tie-ups, integrating its digital health platforms and AI with GRAIL’s cancer-detection technologytradingview.comprnewswire.com.
